SUMMARY OF CHANGES. Section : Site initiation Patients questionnaires, «including Qualisex (Ancillary study questionnaire- See Appendix 17.
|
|
- Felicity Lee
- 5 years ago
- Views:
Transcription
1
2
3 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) SUMMARY OF CHANGES 1- Qualisex questionnaire Background: This ancillary study to ECLAIR is set up to measure the impact of certolizumab pegol (CZP) treatment on sex life of patients suffering from RA, assessed by Qualisex questionnaires, as an additional quality of life parameter. Summary of modifications brought to the below-mentioned sections Section 1: Summary Qualisex questionnaire added Section 3.2 : Secondary objectives An additional secondary objective added: The impact of the treatment on quality of sexual life as measured by the Qualisex questionnaire (see Appendix 17.2) Section 4.1.2: Secondary variables An additional secondary variable added: Change from Baseline at 3, 6, 12, 18, 24 and 36 months in patient s quality of sexual life as measured by the Qualisex questionnaire Section 5.2.: Schedule of Study assessments An additional assessment added: Qualisex questionnaire (See Appendix 17.2) performed at each visit. Section 8.2. : From the patients Qualisex questionnaire added Section : Site initiation Patients questionnaires, «including Qualisex (Ancillary study questionnaire- See Appendix 17.2)» Section : Patients inclusion- Hospital rheumatologists and internal medicine specialists Give the patient HAQ-DI, SF-36 and Qualisex Baseline questionnaires. The questionnaires will be filled in by the patient alone in the physician's office. 3
4 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Section : Patients inclusion- Private rheumatologists and general practitioners «Patients questionnaires, including Qualisex (Ancillary study questionnaire)» Section 8.5. :Follow-up HAQ-DI, SF-36 and Qualisex follow-up questionnaires will be filled in by the patient in the physician's office and handed in to the physician who will send them in a pre-paid envelope provided by REGISTRAT-MAPI. Section 9.8.: Qualisex Questionnaire (see Appendix 17.2) added Qualisex questionnaire is a simple and valid tool investigating impact of RA on sexuality. A 10- question questionnaire was constructed, with assessement by numeric rating scale from 0 (no impact of RA) to 10 (full impact of RA). The questionnaire contains 2 general questions, 1 question on negative aspect of medication, 2 on self-perception, 2 on couple/relationship, 2 on RA related physical difficulties and 1 on performance. An answer modality not applicable allows this questionnaire to be distributed to all patients whatever the situation (single or with a partner). The validated of Qualisex questionnaire in French will be used in this study. The patient will be prompted to complete the questionnaire at the physician s office and handed in to the physician who will send it in a pre-paid envelope provided by REGISTRAT-MAPI.together with SF36 The questionnaire will be used in parallel to SF-36 at baseline and after 12 months and also in all follow-up visits, as an additional secondary objective in ÉCLAIR study. This evaluation will be conducted among a subgroup of patients after implementation of this amendment. Section : Analyses of secondary variables Qualisex added The scores of the 8 dimensions (Physical functioning, Role-physical limitations, Bodily pain, General health, Vitality, Mental health, Role-emotional limitations, Social functioning) and 2 summary measures (Physical component summary score and Mental component summary score) of the SF-36 and Qualisex questionnaire will be described at each visit and changes from Baseline will be computed at each follow up visit. 4
5 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Section 12.8.: Sample size calculation for the ancillary study added (see Appendix 17.2) Sample size calculation for the ancillary study: The primary objective of the ancillary study is to evaluate CZP impact on sexual life at 12 months compared to baseline assessed by Qualisex questionnaire using 10 questions scored from 0 (minimum impact on sexuality) to 10 (maximum impact ). An overall score is calculated by averaging the responses and therefore varies from 0 to 10. Secondary objective of the ancillary study is to evaluate this score during follow-up visits versus baseline. The number of subjects required is calculated to ensure a satisfactory level of accuracy to describe the response at 12 months. The data available in the literature are taken from the article "Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement" Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G, Sordet C,.Perdriger A. - Clinical and experimental Rheumatology. Qualisex average score obtained among 53 patients was 3.3 (+ / -2.5). In the ancillary study, the inclusion of 300 to 400 patients will be sufficient to compute the average score for patients answering the questionnaire with an accuracy of + / around an average score of 3.3 and detect a significant change(around 24%) in the score from 12 months versus baseline(assumption of a change of 0.8 between baseline and one year). Considering a variation of the mean score of 2.5 (standard deviation), a bilateral significance level α of 5%, a significance level β of 10% (90% power), a CZP treatment maintenance level at 65% at one year and a drop-out rate at 20%, the calculation leads to a subgroup of 335 patients to be included. The calculation is performed with SAS (Proc Power - Onesamplemeans). Section 15.: Ancillary study references added HELLAND Y, et al.: Rheumatic diseases and sexuality : Disease impact and self management strategies. Arthritis Care Res (Hoboken) Jan 10. (Epub ahead of print) Pub Med PMID: Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G, Sordet C,.Perdriger A. : Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. Clin Exp Rheumatol. 5
6 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Section 17.2.: APPENDIX 2: Ancillary Study Protocol added EVALUATION OF CIMZIA (CERTOLIZUMAB PEGOL) TREATMENT ON SEXUAL LIFE OF PATIENT SUFFERING FROM RA ASSESSED BY QUALISEX QUESTIONNAIRE. Background: This ancillary study to ÉCLAIR is set up to measure the impact of certolizumab pegol (CZP) treatment on sex life of patients suffering from RA, assessed by Qualisex questionnaires, as an additional quality of life parameter. Little is known about the characteristics of RA difficulties in sex life compared to other inflammatory disorders (1-) as well as about treatment effect on this parameter. Qualisex questionnaire, a simple (10 questions) and valid tool investigating impact of RA on sexuality, has been developed by Professor Perdriger s team after a 10 year collaboration with sexologists, rheumatologists and patients. This new tool can be useful to assess this important, though neglected, aspect of quality of life as well as the efficacy of CZP treatment on it. The questionnaire will be used in parallel to SF-36 at baseline and after 12 months and also in all follow-up visits, as an additional secondary objective in ÉCLAIR study. This evaluation will be conducted among a subgroup of patients after implementation of this amendment. Number of subjects required in ÉCLAIR study: The main study is aiming at 750 enrolled patients. As of end of July, 520 patients still need to be enrolled. The remaining patients still to be enrolled are sufficient to answer the question of the ancillary study using "Qualisex"tool. Additionnally, the calculation of required number of patients for this ancillary study will be integrated in the amended study protocol (amendment n 2). ECLAIR primary objective: The main objective of ECLAIR is to describe the disease outcome at 12 months, in patients with moderate to severe active RA treated with CZP, assessed by the EULAR response criteria: responders (good or moderate response) and non- responders (no response), based on the DAS 28 (ESR) score. The sample size of the study was computed to ensure a satisfactory level of accuracy to describe the EULAR response at 12 months. A population of 323 patients is sufficient to estimate with a 95% confidence interval, a response of 60% to 80% with an acceptable precision of around 5%. To get 323 analyzable patients still under CZP at week 52, it was planned in the protocol to include 750 patients considering a lower treatment maintenance rate of 55% at 12 months and a drop-out rate at 20%. 6
7 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) 520 patients are still likely to be included in the ÉCLAIR study. Sample size calculation for the ancillary study: The primary objective of the ancillary study is to evaluate CZP impact on sexual life at 12 months compared to baseline assessed by Qualisex questionnaire using 10 questions scored from 0 (minimum impact on sexuality) to 10 (maximum impact ). An overall score is calculated by averaging the responses and therefore varies from 0 to 10. Secondary objective of the ancillary study is to evaluate this score during follow-up visits versus baseline. The number of subjects required is calculated to ensure a satisfactory level of accuracy to describe the response at 12 months. The data available in the literature are taken from the article "Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement" Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G, Sordet C,.Perdriger A. - Clinical and experimental Rheumatology. Qualisex average score obtained among 53 patients was 3.3 (+ / -2.5). In the ancillary study, the inclusion of 300 to 400 patients will be sufficient to compute the average score for patients answering the questionnaire with an accuracy of + / around an average score of 3.3 and detect a significant change(around 24%) in the score from 12 months versus baseline(assumption of a change of 0.8 between baseline and one year). Considering a variation of the mean score of 2.5 (standard deviation), a bilateral significance level α of 5%, a significance level β of 10% (90% power), a CZP treatment maintenance level at 65% at one year and a drop-out rate at 20%, the calculation leads to a subgroup of 335 patients to be included. The calculation is performed with SAS (Proc Power - Onesamplemeans). Since this number of patients is lower than the one remaining to be included in the ÉCLAIR study, it is thus possible to perform this ancillary study. 7
8 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) References: 1- HELLAND Y, et al.: Rheumatic diseases and sexuality : Disease impact and self management strategies. Arthritis Care Res (Hoboken) Jan 10. (Epub ahead of print) Pub Med PMID: Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G, Sordet C,.Perdriger A. : Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. Clin Exp Rheumatol. Qualisex questionnaire added 8
9 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Qualisex questionnaire- English (1/2) 9
10 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Qualisex questionnaire- English (2/2) 10
11 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Qualisex questionnaire- French (1/2) 11
12 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Qualisex questionnaire- French (2/2) 12
13 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) 2- Contact Information Modification n 1 from: Clinical Project Manager Name: Address: Ghislaine Lizon (REGISTRAT-MAPI) 27, rue de la Villette LYON, France Phone: Fax: To: Clinical Project Manager Name: Virginie Duroyon (REGISTRAT-MAPI) Address: 27, rue de la Villette LYON, France Phone: Modification n 2 from: Clinical Trial Biostatistician Name: BOUSSETTA Sami (REGISTRAT-MAPI) Address: 27, rue de la Villette LYON, France Phone: Fax:
14 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) To: Clinical Trial Biostatistician Name: VIDAL Chrystelle (REGISTRAT-MAPI) Address: 27, rue de la Villette LYON, France Phone: Fax: Study timelines - Section 1- Summary Modification from: Study timelines First Patient first visit (FPFV) December 2011 Last Patient first visit (LPFV) December Last Patient last visit (LPLV) December 2015 Interim analysis Report (IAR) March 2015 Final statistical report (FSR) March 2016 To: Study timelines First Patient first visit (FPFV) December 2011 Last Patient first visit (LPFV) December Last Patient last visit (LPLV) December 2015 First Interim analysis Report (FIAR) March 2013 Second Interim analysis Report (SIAR) March 2014 Final statistical report (FSR) March
15 31 July Addition of an ancillary study: Evaluation of Cimzia (Certolizumab pegol) Planned Interim analysis- Section Modification from: Two interim analyses will be performed for all patients included: - The first interim analysis after 1-year follow-up (i.e., 12-month visit) - The second interim analysis after 2-year follow-up (i.e., 24-month visit) To: Two interim analyses will be performed for all patients included: - The first interim analysis after 1-year follow-up (i.e., 12-month visit) - The second interim analysis after 2-year follow-up (i.e., 24-month visit) - In addition, a descriptive analysis will be performed for all enrolled patients at the end of the inclusion period 15
Updates to the Alberta Drug Benefit List. Effective January 1, 2018
Updates to the Alberta Drug Benefit List Effective January 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationCimzia (certolizumab pegol)
DRUG POLICY BENEFIT APPLICATION Cimzia (certolizumab pegol) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationExtrapolation in paediatric juvenile idiopathic arthritis: case study
Extrapolation in paediatric juvenile idiopathic arthritis: case study Ruth Oliver, PhD Laura Shaughnessy, PhD Philippa Charlton, MD MPH 17.MAY.2016 EMA workshop Extrapolation in juvenile idiopathic arthritis
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Summit Medical Group. Standardizing Protocols and Educating Providers
Best Practices in Managing Patients with Rheumatoid Arthritis Summit Medical Group Standardizing Protocols and Educating Providers Organizational Profile Summit Medical Group, established in 1929, is the
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationRheumatoid Arthritis Learning Collaborative
Add your company logo Add here your company logo here Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie June 11, 2015 Group Update Sutter Medical Group of the Redwoods/Sutter Pacific
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationBARBADOS MAY Caribbean Association for Rheumatology Meeting. May 15 th - 16 th Barbados Hilton Resort. Hosted by-:
BARBADOS MAY 2015 Caribbean Association for Rheumatology Meeting May 15 th - 16 th Barbados Hilton Resort Hosted by-: For more information go to www.rmbmedical.com Email conferences@rmbmedical.com For
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationValidation of the Russian version of the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA Scale)
Advances in Medical Sciences Vol. 54(1) 2009 pp 27-31 DOI: 10.2478/v10039-009-0012-9 Medical University of Bialystok, Poland Validation of the Russian version of the Quality of Life-Rheumatoid Arthritis
More informationTitle 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* Section/item Item No Description Addressed on page number Administrative information Title 1 Descriptive
More informationHealth Related Quality of Life before, during and after pregnancy in Norwegian women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.
Health Related Quality of Life before, during and after pregnancy in Norwegian women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. Bente Jakobsen Master Thesis in Clincical Health Science
More informationPatient Outcomes in Rheumatoid Arthritis
Patient Outcomes in Rheumatoid Arthritis The impact of rheumatoid arthritis on patients quality of life A small qualitative study involving 25 patients with rheumatoid arthritis in Sweden looked at the
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationChanges in Benefit Status and Criteria Update: Topiramate
JANUARY 2016 Nova Scotia Formulary Updates Changes in Benefit Status and Criteria Update Topiramate Change in Benefit Status Escitalopram Criteria Update Actemra Januvia and Janumet Cimzia New Product
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationRoyal Free and University College Medical School University College London
Royal Free and University College Medical School University College London Academic Centre for Medical Education 4 th Floor Holborn Union Building Archway Cpus Highgate Hill London N19 3UA Dr In Haq Telephone:
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationPatient Engagement Improving Outcomes for Patients with Rheumatoid Arthritis
Patient Engagement Improving Outcomes for Patients with Rheumatoid Arthritis Ryan Antolini, M.D. Timothy Gensler, M.D. John Janas, M.D. Presenters Denver Arthritis Clinic Ryan Antolini, M.D. Board Certified
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More information1 Does Maintained Spinal Manipulation Therapy for Chronic Nonspecific Low Back Pain Result in Better Long-Term Outcome?
1 Does Maintained Spinal Manipulation Therapy for Chronic Nonspecific Low Back Pain Result in Better Long-Term Outcome? Randomized Trial SPINE August 1, 2011; Volume 36, Number 18, pp. 1427 1437 Mohammed
More informationTocilizumab F. Hoffmann-La Roche Ltd. Protocol MA 27950, Version 3.0 1
Protocol MA 27950, Version 3.0 1 Protocol MA 27950, Version 3.0 2 TABLE OF CONTENTS PROTOCOL ACCEPTANCE FORM... 8 PROTOCOL SYNOPSIS... 9 1. BACKGROUND... 15 1.1 Background on Rheumatoid Arthritis... 15
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationIntegrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data
Integrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles,
More informationSAMPLE IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI:
Please Note: Medical Necessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATION
More informationAuthor's response to reviews
Author's response to reviews Title: Comparison of health-related quality of life between housewives and employed women in Zahedan City, Southeast Iran during 2009-2010 : A cross-sectional study Authors:
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 22:54:26 GMT) CTRI Number Last Modified On 11/05/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationA Clinical Context Report
Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationStudy Design: Prospective observational study of cervical interlaminar injection of steroid in patients with cervical radicular pain
Study Design: Prospective observational study of cervical interlaminar injection of steroid in patients with cervical radicular pain Background and Significance To be completed by the project s Principal
More informationJane T Osterhaus 1* and Oana Purcaru 2
Osterhaus and Purcaru Arthritis Research & Therapy 2014, 16:R164 RESEARCH ARTICLE Open Access Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing
More informationTechnology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247
Tocilizumab for the treatment of rheumatoid arthritis Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER. Volume: Page:
SYNOPSIS Protocol No: OROS-ANA-3001 Title of Study: Randomized, open-label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationBiotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1
IQWiG Reports Commission No. A10-01 Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1 Executive Summary 1 Translation of the executive summary of the final report Biotechnologisch
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTITLE: Biologics Dose Escalation for the Treatment of Rheumatoid Arthritis: A Review of the Clinical and Cost-Effectiveness
TITLE: Biologics Dose Escalation for the Treatment of Rheumatoid Arthritis: A Review of the Clinical and Cost-Effectiveness DATE: 22 September 2015 CONTEXT AND POLICY ISSUES Rheumatoid arthritis (RA) is
More informationAuthor's response to reviews
Author's response to reviews Title: Comparison of health-related quality of life between housewives and employed women in Zahedan City, Southeast Iran during 2009-2010 : A cross-sectional study Authors:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More informationRAPID3? Aptly named!
RAPID3? Aptly named! J.-M. Berthelot Rheumatology Unit, Nantes University Hospital, Nantes, France. Jean-Marie Berthelot, MD Please address correspondence to: Jean-Marie Berthelot, Rheumatology Unit, Nantes
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationMeda Pharmaceuticals
MP03-33 Nasal Spray Page 1 of 9 Meda Pharmaceuticals Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis (MP432) FINAL CLINICAL STUDY
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationNewer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis?
Newer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis? DR MD MATIUR RAHMAN MBBS, MD, FCPS, FACR, Fellow APLAR Associate Professor, Medicine SSMC & Mitford Hospital New
More informationMeasure #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Measure #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: Percentage
More informationPragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care
S30 Pragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care Theodore Pincus, M.D., Yusuf Yazici, M.D., and Isabel Castrejón, M.D. Abstract
More informationHealth Status Instruments / Utilities
Workshop Report Health Status Instruments / Utilities NICHOLAS BELLAMY, MAARTEN BOERS, DAVID FELSON, JAMES FRIES, DANIEL FURST, DAVID HENRY, MATTHEW LIANG, DANIEL LOVELL, LYN MARCH, VIBEKE STRAND, and
More informationLupusPRO (Lupus Patient Reported Outcome Tool) v1.7
LupusPRO (Lupus Patient Reported Outcome Tool) v1.7 Authors: Meenakshi Jolly and Simon Pickard For information on, or permission to use tool, please contact: Meenakshi Jolly, MD Assistant Professor of
More informationElectronic MDHAQ / T. Pincus
Electronic multidimensional health assessment questionnaire (emdhaq): past, present and future of a proposed single data management system for clinical care, research, quality improvement, and monitoring
More informationQuality of Life of HIV-infected Patients Study
Investigator Name: Quality of Life of HIV-infected Patients Study OptumInsight is seeking for additional investigators for a multicenter longitudinal observational study involving adult patients with HIV.
More information2.0 Synopsis. Adalimumab DE018 OLE (5 year) Clinical Study Report R&D/06/369. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study: A Multi-center
More informationQuality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationImprovements in pain were observed from week 1 and for fatigue and physical function from week 2 vs placebo
Medical / trade Psoriatic arthritis (PsA) patients treated with Cimzia reported improvements in physical function, fatigue and pain and increased productivity at work and within the home Improvements in
More information1.2. Protocol number 6078-PG-PSC EU trial number
1. Clinical trial identification Researchers look at the results of many studies to decide which drugs work best and are safest for patients. It takes participants in many studies all around the world
More informationWhat does it mean for Pharmacists?
18th Congress of the European Association of Hospital Pharmacists (EAHP) Paris, 14 March 2013 What does it mean for Pharmacists? Value-based Decision Making in Rheumatic Disease Pr. REES France 28, Rue
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Cornerstone Health Care, P.A. Collecting and Measuring RA Data
Best Practices in Managing Patients with Rheumatoid Arthritis, P.A. Collecting and Measuring RA Data Organizational Profile opened in 1995 in High Point, North Carolina, as a multidisciplinary group of
More informationConcept of Measurement: RA Defining Decrements in Physical Function
Concept of Measurement: RA Defining Decrements in Physical Function Vibeke Strand, MD Biopharmaceutical Consultant Adjunct Clinical Professor, Division of Immunology, Stanford University Disclosures: Consultant
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationChapter 3 - Does Low Well-being Modify the Effects of
Chapter 3 - Does Low Well-being Modify the Effects of PRISMA (Dutch DESMOND), a Structured Selfmanagement-education Program for People with Type 2 Diabetes? Published as: van Vugt M, de Wit M, Bader S,
More informationOpinion 1 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2014 CIMZIA 200 mg, solution for subcutaneous injection 1 B/2 1 ml prefilled syringes with needle guard
More informationDescription of Study Protocol. Data Collection Summary
AND Evidence Analysis Worksheet Citation Kostoglou-athanassiou I, AthanassiouP, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. 2012; 3(6):181-7. Study
More informationWAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED?
WAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED? Ashley Delaurier PT M.Sc. Candidate Biomedical Sciences University of Montreal ashley.delaurier@umontreal.ca
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Add your company logo here Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 USMD Health System RA Collaborative 2 Medical Group Profile USMD Health System:
More informationDivision of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education & Research RIPER, Anantapuramu, Andhra Pradesh, INDIA.
Original Article Impact of Clinical Pharmacist Mediated Patient Counseling on Health Related Quality of Life in Rheumatoid Arthritis Patients in Healthcare Resource Limited Settings of India Mohanraj Rathinavelu
More informationFollow-up Visit Procedures MTN-009
Follow-up Visit Procedures MTN-009 General Overview MTN-009 follow-up visits are only required for participants who are found to be HIV infected These participants will have a minimum of two follow-up
More informationCimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Rapid, sustained and clinically meaningful improvement in wideranging patient-reported
More informationStudy Design: Prospective observational study of cervical transforaminal epidural steroid injections in patients with cervical radicular pain
Study Design: Prospective observational study of cervical transforaminal epidural steroid injections in patients with cervical radicular pain Background and Significance To be completed by the project
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs Thank you for agreeing to give us a statement on your organisation's view
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationRe: Healthy Behaviors Rewards Program. Dear Plan Member,
WLREFER.01012016 Re: Healthy Behaviors Rewards Program Dear Plan Member, GOOD NEWS! You have been referred to the Healthy Behaviors Rewards Program checked below. The referral may have come from your doctor,
More informationINCREASING REPRESENTATION IN A MIXED-MODE QUALITY OF LIFE SURVEY OF MEDICARE ESRD BENEFICIARIES
ACADEMY HEALTH 2018 INCREASING REPRESENTATION IN A MIXED-MODE QUALITY OF LIFE SURVEY OF MEDICARE ESRD BENEFICIARIES Speaker: Katherine Harris, Principal Research Scientist Team Members: Amy L. Djangali,
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More information1.0 Abstract. Title P13-562
1.0 Abstract Title P13-562 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn s Disease and Ulcerative Colitis patients`adherence attitudes to maintenance
More informationPatient Reported Quality of Life in an Early Psoriatic Arthritis Cohort
26 Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort Majed Khraishi 1 2, Jennifer Hulburt, Sarah Khraishi and Courtney Youden 2 1 Memorial University of Newfoundland, St. John s,
More informationStudy synopsis of the global non-interventional study SWITCH-RA
Study synopsis of the global non-interventional study SWITCH-RA Protocol number: MA22401 Title of Study: A global multi-centre observational study in RA patients who are non-responders or intolerant to
More informationOxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France
Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,
More informationTeledermatology Experience at Uconn. Jun Lu, M.D. Assistant Professor Director of Teledermatology Department of Dermatology University of Connecticut
Teledermatology Experience at Uconn Jun Lu, M.D. Assistant Professor Director of Teledermatology Department of Dermatology University of Connecticut Teledermatology at University of Connecticut Store-and-forward
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More informationRheumatoid Arthritis Learning Collaborative
Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 12 14, 2015 USMD Rheumatoid Arthritis Collaborative Medical Group Profile USMD Health System: May 7, 2010 Medical Clinic
More informationPrimary Care Services for blood borne viral hepatitis prevention, treatment and care
Primary Care Services for blood borne viral hepatitis prevention, treatment and care Author: Josie Smith, Marion Lyons Page 1 of 13 October 2006 Status : Final Contents: Page: Executive Summary 3 Introduction
More informationJennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
More informationPatient group: adults with a diagnosis of rheumatoid arthritis (RA)
eumusc.net HCQI RA 1 If a patient presents with suspected rheumatoid arthritis (RA) then he/she should be referred to and seen by a specialist (preferably a rheumatologist) for confirmation of diagnosis
More information